The Art Institute of Atlanta Announces Ozzie Areu as Keynote Speaker
Reading Time: 4 minutes
ATLANTA–(BUSINESS WIRE)–The Art Institute of Atlanta is pleased to announce Ozzie Areu, Founder
and CEO Areu Bros. Studios, as the keynote speaker of their 2019
commencement ceremony. The event will take place on Friday, June 14,
2019, at 11:00 a.m. at Cobb Energy Performing Arts Centre, located at
2800 Cobb Galleria Parkway, Atlanta, GA 30339. www.artinstitutes.edu/atlanta
Mr. Newton I. Myvett, President of The Art Institute of Atlanta, said: “We
are honored to have someone with the vision and industry expertise of
Ozzie Areu as this year’s keynote speaker. Our academic programs
are formulated with industry input to ensure students are equipped with
skills and competencies that are aligned with industry standards. Having
Mr. Areu as the keynote speaker of our commencement ceremony will give
our graduates insightful, hard-won knowledge that will propel them to
success.”
Cuban-American producer Ozzie Areu is the Founder & CEO of Areu Bros.
Studios, the first Latino-owned and operated film and television studio
in the United States. www.areubros.com
Ozzie’s introduction to the entertainment industry began with a security
guard position at Warner Bros. His tireless work ethic led him to be the
head of security for “Friends,” which opened doors for him such
as becoming a personal assistant to Jennifer Aniston and Brad Pitt for
five years, followed by two years with Ellen DeGeneres and Portia De
Rossi. He was then hired by Tyler Perry to be his Executive Assistant.
Ozzie began commuting from Los Angeles to Atlanta in order to stay close
to his family until his family encouraged him to make the move and try
to learn as much as possible from a visionary and pioneer such as Tyler
Perry. Ozzie was promoted from assistant to President of Tyler Perry
Studios just about a year after starting with Tyler.
Since his start as President of Tyler Perry Studios, where Ozzie also
served as Executive Producer, he has become a trailblazer in the
entertainment industry. During his fruitful career, Ozzie has made many
films and produced over 900 episodes of television dramas and sitcoms
over nine different series. Ozzie helped manage Tyler Perry Studios’
vision for his company, “A Place Where Even Dreams Believe,”
intertwining worlds through storytelling and family-friendly
entertainment, while inspiring audiences with real-life and
thought-provoking issues.
Ozzie also helmed 34th Street Films, a Tyler Perry Production arm that
discovered the film Precious while at Sundance Film Festival in
2009. Precious garnered two Academy Awards in 2010 for Best
Supporting Actress and Best Writing Adapted Screenplay, while also
winning a Golden Globe Award, an NAACP Award and an Independent Spirit
Award.
After 13 years of working for Tyler Perry he left his post as President
to become the Owner and Founder of Areu Bros. Studios. Ozzie purchased
Tyler Perry’s former studio complex in December 2018 in Southwest
Atlanta, with the aim of transforming it into a multifaceted media
campus encompassing music, tech, short-form content, motion pictures and
television operations.
Ozzie has a long list of production work that includes many of Tyler
Perry’s sitcoms like TBS’s highest rated comedy House of Payne,
the popular Meet the Browns, For Better and for Worse, The
Haves and the Have Nots and Love Thy Neighbor, just to name a
few. The Haves and the Have Nots set records for OWN, scoring the
highest ratings ever for a series premiere and the highest overall
ratings in the network’s history. Love Thy Neighbor acquired the
second highest-rated series program on the OWN Network after The
Haves and the Have Nots.
Film production credits include: For Colored Girls, Madea’s
Big Happy Family, his first animation Madea’s Tough Love, Good
Deeds, Madea’s Witness Protection, Temptation: Confessions
of a Marriage Counselor, Peeples, Single Mom’s Club, A
Madea Christmas, Boo! A Madea Halloween, Boo 2! A Madea
Halloween, Acrimony, A Madea Family Funeral and many
more.
Ozzie has worked with A List talent such as Sofía Vergara, Janet
Jackson, Whoopi Goldberg, Taraji P. Henson, Phylicia Rashad, Eugene
Levy, Doris Robert, Nia Long, Thandi Newton, Kerry Washington, Loretta
Devine, Wendi McLendon-Covey, Kathy Najimy, John Schneider, Zulay Henao
and many more.
Awards: The 50 Most Influential Latinos in Georgia and The Presidents’
Award by The Georgia Hispanic Chamber of Commerce, The Eagle Leadership
Award by The Latino Leaders Network, The Global Cultural Hero and
Outstanding Georgia Citizen Awards by the World Chamber of Commerce, For
Colored Girls received honors at the NAACP Image Awards including
Outstanding Supporting Actress in a Motion Picture, Outstanding
Directing for a Motion Picture/Television Movie for Tyler Perry and
Outstanding Motion Picture. At the 2011 BET Awards, For Colored Girls
received top honors with Best Picture.
Additional Awards include the Georgia Highlight Award (2015) and the
Who’s Who Top 100 Presidents (2015). The Hispanicize Latinovator Award
(2016), American Diabetes Association (2016), Father of the Year Award
(2016), CEO Executive Excellence in Entertainment Award by the Georgia
Hispanic Chamber of Commerce (2016), Men In Black Award (2016) and was
also recognized by Fox News Channel for Hispanic Heritage Month (2016).
He and his brother received the 2017 Untold Stories Honorees by the
Black Women Film Network and were featured in CNN Money: My American
Success Story.
The Art Institute of Atlanta has a tradition of quality, career
focused-education for the creative field. Founded in 1949 as Massey
Business College, the college became The Art Institute of Atlanta in
1975 and is proud of its more than sixty-year legacy of education for
creative professionals. It offers degree programs in the areas of
Design, Fashion, Media Arts and Culinary. The Art Institute of Atlanta
houses a gallery exhibition space, and is home to Creations, its
student-run restaurant, which is open to the public. The Art Institute
of Atlanta is accredited by the Southern Association of Colleges to
award associate and baccalaureate degrees. Contact the Commission on
Colleges at 1866 Southern Lane, Decatur, Georgia 30033-4097 or call
404.679.4500 for questions about the accreditation of The Art Institute
of Atlanta. For More Information on the Art Institute of Atlanta, please
visit www.artinstitutes.edu/atlanta.
The Art Institute of Atlanta is one of The Art Institutes, a system of
private, non-profit schools throughout the United States. Programs,
credential levels, technology and scheduling options vary by school and
are subject to change. 6600 Peachtree Dunwoody Rd, NE, Embassy Row,
Atlanta Georgia 30328. © 2019. The Arts Institutes International LLC.
All rights reserved.
Contacts
Press Contacts:
Marcia Gomez
(305) 397-9207
Camille Cortes
(787) 390-1980
[email protected]
TORONTO and GLIL YAM, Israel, Sept. 11, 2024 /PRNewswire/ — IM Cannabis Corp. (“IMC” or the “Company“) (NASDAQ: IMCC) (CSE: IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. Shmulik Arbel has been appointed to the Company’s board of directors (the “Board“) effective September 9, 2024. Mr. Arbel brings a wealth of experience in strategic plans that drive profitability, as well as, finance and corporate governance, further strengthening the company’s commitment to driving growth while focusing on sustainable profitability.
“We are thrilled to welcome Shmulik to our Board of Directors,” said Oren Shuster, Chief Executive Officer of IM Cannabis. “Shmulik’s extensive international experience at Leumi, coupled with his proven track record in banking and finance will be invaluable as we continue to deliver on our strategic initiatives.”
Mr. Arbel retired as Deputy CEO from Leumi, Israel’s largest banking group, in April 2023, where he was instrumental in business growth and leading the service revolution. With over 25 years of experience at Leumi, Arbel has held senior roles throughout the organization, such as head of retail banking, head of the corporate division, and as chairman of Leumi UK. With key roles in Israel, New York and London, Mr. Arbel has a wide view on international business.
“I am honored to join the Board of Directors at IMCC,” said Mr. Arbel. “I look forward to leveraging my experience in banking and finance, providing guidance as IMCC continues to establish itself as the go-to brand in the cannabis world. I look forward to contributing to the company’s growth.”
Arbel holds a BA and MBA from Tel Aviv University.
About IM Cannabis Corp.
IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has focused its resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.
The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.
Disclaimer for Forward-Looking Statements
This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, “forward-looking statements“). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to: the stated benefits Mr. Arbel’s appointment, including the further strengthening the Company’s commitment to driving growth in the German market while focusing on sustainable profitability; and Mr. Arbel’s international experience and track record in banking and finance will be invaluable to the Company.
Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the Company’s ability to realize upon the stated benefits Mr. Arbel’s appointment; and Mr. Arbel’s international experience and track record in banking and finance becoming invaluable to the Company.
The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company’s ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and its subsidiaries (collectively, the “Group“) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest in Eastern Europe and the Middle East, including the impact of the Israel-Hamas war on the Company, its operations and the medical cannabis industry in Israel; risks associated with the Company focusing on the Israel and Germany markets; the inability of the Company to achieve sustainable profitability and/or increase shareholder value; the inability of the Company to actively manage costs and/or improve margins; the inability of the company to grow and/or maintain sales; the inability of the Company to meet its goals and/or strategic plans; the inability of the Company to reduce costs and/or maintain revenues; the Company’s inability to take advantage of the legalization of medicinal cannabis in Germany; and the Company’s inability to realize upon the stated benefits Mr. Arbel’s appointment; and Mr. Arbel’s international experience and track record in banking and finance not becoming valuable to the Company.
Please see the other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual report dated March 28, 2024, which is available on the Company’s issuer profile on SEDAR+ at www.sedarplus.ca and Edgar at www.sec.gov/edgar. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.
Company Contact:
Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]
Oren Shuster, CEO
IM Cannabis Corp.
[email protected]
Logo: https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/im-cannabis-announces-appointment-of-shmulik-arbel-to-board-of-directors-302244961.html
Indivior
Indivior Provides Update on Aelis Farma’s Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018).
- Primary and Secondary End Points of the Study were Not Met
- Indivior Does Not Currently Expect to Exercise AEF0117 Option
SLOUGH, United Kingdom and RICHMOND, Va., Sept. 4, 2024 /PRNewswire/ — Indivior PLC (Nasdaq/LSE: INDV) is today providing an update following Aelis Farma’s announcement of the results from its clinical Phase 2B trial with AEF01171, evaluating the efficacy and safety in treatment-seeking participants with moderate to severe Cannabis Use Disorder (CUD). The purpose of this trial was twofold: (1) to show that AEF0117 (0.1, 0.3, 1 mg once a day for 12 weeks) lowers cannabis use and (2) to determine the endpoints and optimal dosage of AEF0117 for use in future studies. In this phase 2B study, patients were treatment-seeking participants, 84% of whom had severe CUD.
The results of the study demonstrated that the primary endpoint, the proportion of participants who reduced their cannabis use to ≤1 day per week, as well as secondary endpoints measuring the proportion of participants reaching either complete abstinence or who used ≤2 day per week, were not met. Although these results are disappointing, they indicate that significant work remains to be done to understand subpopulations of patients with CUD, specifically those with severe CUD.
This clinical Phase 2B study is part of the strategic collaboration between Aelis Farma and Indivior, which includes an exclusive option for Indivior to license the global rights to AEF0117. Given the lack of separation from placebo on primary and secondary endpoints and before seeing further additional favorable clinical data, Indivior does not currently expect to exercise its option.
Important Cautionary Note Regarding Forward-Looking Statements
This news release contains certain statements that are forward-looking. Forward-looking statements include, among other things, express and implied statements regarding whether: we will be able to ultimately demonstrate the safety and efficacy of AEF0117, which is a prerequisite to filing any New Drug Application; we might ever exercise our option for AEF0117 and, if so, when; and other statements containing the words “believe,” “anticipate,” “plan,” “expect,” “intend,” “estimate,” “forecast,” “strategy,” “target,” “guidance,” “outlook,” “potential,” “project,” “priority,” “may,” “will,” “should,” “would,” “could,” “can,” “outlook,” “guidance,” the negatives thereof, and variations thereon and similar expressions. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future.
Actual results may differ materially from those because they relate to future events. Various factors may cause differences between Indivior’s expectations and actual results, including, among others, the risks described in our most recent annual report on Form 20-F beginning on page 9 as filed with the U.S. SEC and in subsequent releases; legal and market restrictions that may limit how quickly we can repurchaser our shares; the substantial litigation and ongoing investigations to which we are or may become a party; our reliance on third parties to manufacture commercial supplies of most of our products, conduct our clinical trials and at times to collaborate on products in our pipeline; our ability to comply with legal and regulatory settlements, healthcare laws and regulations, requirements imposed by regulatory agencies and payment and reporting obligations under government pricing programs; risks related to the manufacture and distribution of our products, most of which contain controlled substances; market acceptance of our products as well as our ability to commercialize our products and compete with other market participants; competition; the uncertainties related to the development of new products, including through acquisitions, and the related regulatory approval process; our dependence on third-party payors for the reimbursement of our products and the increasing focus on pricing and competition in our industry; unintended side effects caused by the clinical study or commercial use of our products; our ability to successfully execute acquisitions, partnerships, joint ventures, dispositions or other strategic acquisitions; our ability to protect our intellectual property rights and the substantial cost of litigation or other proceedings related to intellectual property rights; the risks related to product liability claims or product recalls; the significant amount of laws and regulations that we are subject to, including due to the international nature of our business; macroeconomic trends and other global developments such as armed conflicts and pandemics; the terms of our debt instruments, changes in our credit ratings and our ability to service our indebtedness and other obligations as they come due; changes in applicable tax rate or tax rules, regulations or interpretations and our ability to realize our deferred tax assets; and volatility in our share price due to factors unrelated to our operating performance or that may result from the potential move of our primary listing to the U.S.
Forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.
This release is being made by Kathryn Hudson, Company Secretary Indivior PLC.
About Indivior
Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat substance use disorders (SUD), overdose and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease.
Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.
References:
- National Library of Medicine (U.S.) (2022, April). Effect of AEF0117 on treatment-seeking patients with cannabis use disorder (CUD) (SICA2). Identifier
NCT05322941 https://www.clinicaltrials.gov/study/NCT05322941
Logo – https://mma.prnewswire.com/media/1814851/Indivior_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/indivior-provides-update-on-aelis-farmas-clinical-phase-2b-study-results-with-aef0117-in-participants-with-cannabis-use-disorder-302237355.html
